| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S4896 R12935 |
Broms (Controls exposed to other treatments), 2020 | Caesarean section | 3 months (or more) before pregnancy or during pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.38 [1.80;3.13] C excluded (control group) |
98/208 2,560/9,393 | 2,658 | 208 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S4897 R12940 |
Broms (Controls unexposed, disease free), 2020 | Caesarean section | 3 months (or more) before pregnancy or during pregnancy excluded | population based cohort retrospective | unexposed, disease free | Adjustment: No |
4.24 [3.23;5.57] C excluded (exposition period) |
98/208 281,654/1,623,483 | 281,752 | 208 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S4966 R13040 |
De Lorenzo (Controls unexposed, disease free), 2020 | Caesarean | at least 1st trimester | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
16.18 [0.71;370.88] C excluded (control group) |
3/3 9/36 | 12 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S4967 R13046 |
De Lorenzo (Controls unexposed, sick), 2020 | Caesarean | at least 1st trimester excluded | retrospective cohort | unexposed, sick | Adjustment: No |
7.80 [0.34;176.35] C excluded (exposition period) |
3/3 13/32 | 16 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 0 studies | NaN [NaN;NaN] | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||